Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer

Next Previous
Trial Profile

Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer

Status: Suspended
Phase of Trial: Phase I/II

Latest Information Update: 19 Aug 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Montanide ISA-51 (Primary) ; Nogapendekin alfa inbakicept (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Pharmacodynamics

Most Recent Events

  • 14 Aug 2026 Planned End Date changed from 30 Dec 2035 to 19 Aug 2026.
  • 31 Jul 2026 Planned initiation date changed from 29 Jul 2026 to 5 Aug 2026.
  • 24 Jul 2026 Planned initiation date changed to 29 Jul 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top